A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma

Ipilimumab is an anti-CTLA4 monoclonal antibody with demonstrated efficacy for metastatic melanoma in randomized controlled trials, including in the first-line setting. Population-based outcomes directly compared with historic chemotherapy treatment in metastatic or unresectable melanoma are lacking...

Descripción completa

Detalles Bibliográficos
Autores principales: Drysdale, Erik, Peng, Yingwei, Nguyen, Paul, Baetz, Tara, Hanna, Timothy P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Original Articles: Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887627/
https://www.ncbi.nlm.nih.gov/pubmed/30789386
http://dx.doi.org/10.1097/CMR.0000000000000582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887627/
https://www.ncbi.nlm.nih.gov/pubmed/30789386
http://dx.doi.org/10.1097/CMR.0000000000000582

Ejemplares similares